pembrolizumab
merck
['lung', 'melanoma', 'pembro']
hr for reduction in dmfs with pembro was 0.64 (0.47-0.88). median not yet reached. most common site was lung. at interim analysis 3, sustained benefit in rfs. #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4